Eurocord, Assistance publique des hôpitaux de Paris (APHP), Institut universitaire d'Hématologie (IUH) Hospital Saint Louis Paris, France.
Blood Rev. 2011 Nov;25(6):255-9. doi: 10.1016/j.blre.2011.06.003. Epub 2011 Jul 20.
Since the first human cord blood transplant, performed in 1988, cord blood banks have been established worldwide for collection and cryopreservation of cord blood for allogeneic hematopoietic stem cell transplant. Umbilical cord blood (UCB) has now become one of the most commonly used source of hematopoietic stem cells for allogeneic transplantation. Today a global network of cord blood banks and transplant centers has been established for a common inventory with an estimated 600,000 UCB have been banked and more than 20,000 UCB units distributed worldwide for adults and children with severe hematological diseases. Several studies have shown that the number of cells is the most important factor for engraftment while some degree of HLA mismatches is acceptable. The absence of ethical concern, and the unlimited supply of cells explain the increasing interest of using cord blood for developing regenerative medicine.
自 1988 年首例人类脐带血移植以来，全球范围内已经建立了脐带血库，用于采集和冷冻保存脐带血，以备异基因造血干细胞移植使用。如今，脐带血已成为异基因移植中最常用的造血干细胞来源之一。如今，已经建立了一个全球性的脐带血库和移植中心网络，以进行共同的库存管理，据估计已经有 60 万份脐带血被储存，并且全球范围内已经分发了超过 20000 份脐带血单位，用于治疗严重血液疾病的成人和儿童。多项研究表明，细胞数量是植入的最重要因素，而一定程度的 HLA 不匹配是可以接受的。不存在伦理问题，并且细胞供应无限，这解释了人们对使用脐带血开发再生医学越来越感兴趣的原因。
